Perioperative Immunotherapy for Resectable Limited-Stage SCLC

This study is testing perioperative immunotherapy — adding an immune checkpoint drug (immunotherapy) before and after surgery — for patients with limited-stage small cell lung cancer (SCLC) that can be surgically removed. The hope is that immunotherapy combined with surgery may reduce the risk of the cancer coming back. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with small cell lung cancer - Your cancer is limited-stage (stage IIB–IIIB) and has been assessed as surgically removable with the intent to cure (R0 resection) - Your cancer has been confirmed by biopsy (tissue or fluid) - You are able to provide written consent and follow the study schedule **You may NOT be eligible if:** - Your cancer has spread widely (extensive-stage SCLC) - Your tumor is not resectable (cannot be surgically removed) - You have significant health conditions that would make surgery or immunotherapy unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.